TSS
BTAI icon

Two Sigma Securities’s BioXcel Therapeutics BTAI Stock Holding History

Two Sigma Securities’s Portfolio BTAI Stock Details BTAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$15.2K Buy
+10,796
New +$12.6K ﹤0.01% 1521
2026
Q1 		– Sell
-17,068
Closed -$27.3K – 1690
2025
Q4 		$27.3K Buy
+17,068
New +$35.2K ﹤0.01% 1141
2025
Q1 		– Sell
-1,082
Closed -$6.47K – 1515
2024
Q4 		$6.47K Buy
+1,082
New +$9.04K ﹤0.01% 1468

Other funds holding BTAI

Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
OCM
Oaktree Capital Management Los Angeles, California $7.21B AUM 45.97% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OFA
Oaktree Fund Advisors Los Angles, California $57.8M AUM 67.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Two Sigma Securities's BTAI Position: Q2 2026 in Review

Two Sigma Securities opened a new position in BioXcel Therapeutics (BTAI) in Q2 2026: 10,796 shares worth $15.2K. The stake represents ﹤0.01% of the portfolio and ranks #1521 among its holdings. This is a return to the name: Two Sigma Securities previously reported a position in BTAI as recently as Q4 2025.

Two Sigma Securities first reported a position in BTAI in Q4 2024 and has held it in 3 quarters since. The position peaked at $27.3K in Q4 2025. 47 funds tracked by Wall St. Rank hold BTAI as of Q2 2026.

  • Two Sigma Securities held 10,796 shares of BioXcel Therapeutics worth $15.2K as of Q2 2026.
  • BioXcel Therapeutics was a new Two Sigma Securities position in Q2 2026.
  • BioXcel Therapeutics made up ﹤0.01% of Two Sigma Securities's portfolio in Q2 2026, its #1521 holding.
  • Two Sigma Securities first reported a position in BioXcel Therapeutics in Q4 2024 and has held it in 3 quarters since.
  • Two Sigma Securities's BioXcel Therapeutics position peaked at $27.3K in Q4 2025.
  • 47 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q2 2026.

Based on Two Sigma Securities's 13F filing for Q2 2026, filed 14 Aug 2026.